-+ 0.00%
-+ 0.00%
-+ 0.00%

AIM ImmunoTech Inks Deal With Thermo Fisher Scientific's PPD Clinical Research Business To Design AIM's Phase 3 Study In Use Of Ampligen Drug

Benzinga·03/02/2026 14:06:02
Listen to the news

AIM ImmunoTech Inc. (NYSE:AIM("AIM" or the "Company") today announced an agreement with the PPD™ clinical research business of Thermo Fisher Scientific to design AIM's anticipated Phase 3 clinical trial in the use of the Company's drug Ampligen in the treatment of late-stage pancreatic cancer.